Coronary Slow-Flow Syndrome: A Review on Natural History of Disease and Best Practices

Prevalence and Diagnosis: Coronary Slow Flow (CSF) occurs in 1-7% of patients undergoing angiography, diagnosed via corrected TIMI frame count (cTFC) exceeding 21 ± 3 frames, alongside scintigraphy and ECG analysis.Key Risk Factors: CSF is linked to cardiovascular risks like hypertension, diabetes, and inflammation, with genetic and psychological factors also playing a role in its development.Clinical Management: Treatment focuses on symptom relief using nitrates calcium channel blockers, statins, and anti-inflammatory agents, alongside lifestyle modifications and stress management.Long-Term Outcomes: CSF can lead to complications like myocardial infarction and left ventricular dysfunction, with a 10-year mortality rate of 15.3%, emphasizing the need for early detection and tailored care.

Coronary slow flow (CSF) poses significant clinical challenges, marked by delayed coronary blood flow despite angiographically normal epicardial arteries. With a prevalence of 1% to 7%, the underlying pathogenesis and clinical manifestations of this condition remain incompletely understood. This review examines the natural history of CSF, including its pathophysiological mechanisms, ranging from inflammatory cascades to microvascular dysfunction. Diagnostic approaches, such as corrected TIMI frame count, scintigraphy, and ECG analysis, provide valuable insights into its complex presentation. Further, the review outlines management strategies, focusing on pharmacological interventions like calcium channel blockers and anti-inflammatory agents. Understanding CSF's natural history is crucial for implementing effective preventive measures, spanning primary to tertiary prevention. Still, further research is essential to fully elucidate its pathophysiology and optimize therapeutic strategies for improving patient outcomes in this complex disorder.